Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea

Inclusion Criteria:

* Adults aged 18 years of age and older
* Dermatologist confirmed diagnosis of rosacea
* Clinician's Erythema Assessment of at least 3 (moderate to severe disease)
* Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.

Exclusion Criteria:

* Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.
* Facial hair, tattoos, or other characteristics that would interfere with erythema assessments
* History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)
* Presence of a pacemaker, implanted defibrillator, or neurostimulator
* Seizure disorder or epilepsy
* Trigeminal Neuralgia within the past year
* Severe coronary disease or recent myocardial infarction within the past 5 years
* Severe autonomic dysfunction (e.g., frequent syncope, hospitalization)
* History of recurrent syncope or unexplained fainting
* Use of brimonidine or oxymetazoline within the past 4 weeks
* Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks
* Severe phymatous rosacea
* Ear deformity, piercings, or other condition that prevents the use of the taVNS device
* Known hypersensitivity to electrode materials
* Patients who are pregnant.